SIRT-1和SUMO-1在I型子宫内膜癌中的表达及意义

The Expression and Significance of SIRT-1 and SUMO-1 in Type I Endometrial Carcinoma

摘要: 目的：探讨沉默信息调节因子相关酶-1 (silent information regulator 1, SIRT-1)及小泛素相关修饰分子-1 (small ubiquitin-related modifier, SUMO-1)在子宫内膜不典型增生及子宫内膜癌中的表达及意义。方法：选取异常子宫内膜组织标本73例作为研究对象，包括I型子宫内膜癌45例、不典型增生28例，选取同期因子宫肌瘤行子宫全切手术正常子宫内膜组织30例作为对照。采用免疫组化方法检测各组中SIRT-1及SUMO-1的表达情况，并分析其与子宫内膜癌不同临床病理特征的关系。结果：1) SIRT-1及其SUMO化修饰蛋白SUMO-1在正常子宫内膜、子宫内膜不典型增生、子宫内膜癌组织中阳性表达率呈递增趋势，且两者在子宫内膜癌中的表达明显高于其他组织，差异有统计学意义(P < 0.05)。2) 不同分化程度、临床分期及淋巴结转移的子宫内膜癌组织中SIRT1蛋白及SUMO-1蛋白的表达阳性率比较，差异均有统计学意义(P < 0.05)。3) 子宫内膜癌组织中SIRT-1与SUMO-1蛋白表达呈正相关(Rs = 0.31, P < 0.05)。结论：I型子宫内膜癌组织中SIRT-1与SUMO-1的表达高于正常及不典型增生子宫内膜组织，且两者在子宫内膜增生癌变过程中存在一定相互作用；SIRT-1有望成为子宫内膜癌基因治疗的新途径。

Abstract: Objective: To examine the expression of silent information regulator 1 (SIRT-1) and small ubiquitin-related modifier1 (SUMO-1) in abnormal endometrial tissues, and investigate the correlation among their expression, clinicopathological parameters and clinical significance. Methods: The specimens of 75 patients with endometrial lesions were selected as the subjects, including 45 cases of type I endometrial adenocarcinoma, and 28 cases of endometrial hyperplasia; 30 cases of normal endometrial tissues from patients undergoing total hysterectomy due to uterine fibroids during the same period were selected as the control group. The expression of SIRT-1 and SUMO-1 in different endometrial tissues was detected by immunohistochemistry. Results: 1) SIRT-1 and its sumo-modified protein sumo-1 showed an increased expression level in normal endometrial, endometrial dysplasia, and endometrial carcinoma tissues, and their expression in endometrial carcinoma was significantly higher than that in other tissues, with statistically significant difference (P < 0.05). 2) The positive rates of SIRT1 and SUMO-1 in endometrial carcinoma tissues with different differentiation degrees, clinical stages and lymph node metastasis were significantly different (all P < 0.05). 3) SIRT-1 and SUMO-1 expressions were positively correlated in endometrial carcinoma tissues (R = 0.31, P < 0.05). Conclusion: The expression of SIRT-1 and SUMO-1 in type I endometrial carcinoma tissues is higher than that in normal and endometrial dysplasia tissues, and they may be involved in the process of endometrial hyperplasia and carcinogenesis. SIRT-1 is expected to be a new approach for gene therapy of endometrial carcinoma.